Comboridity of chronic obstructive pulmonary disease and cardiovascular diseases: general factors, pathophysiological mechanisms and clinical significance

Cover Page

Cite item

Full Text

Abstract

Currently, the comorbidity (combination) of chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) is an important problem for the health care. This is due to the high prevalence and continuing growth of these pathologies. CVD and COPD have common risk factors and mechanisms underlying their development and progression: smoking, inflammation, sedentary lifestyle, aging, oxidative stress, air pollution, and hypoxia. In this review, we summarize the current knowledge related to the prevalence and frequency of cardiovascular diseases in people with COPD and the mechanisms that underly their coexistence. The implications for clinical practice, in particular the main problems of diagnosis and treatment of COPD/CVD comorbidity, are also discussed.

About the authors

A. M. Chaulin

Samara Regional Cardiology Dispensary; Samara State Medical University

Author for correspondence.
Email: alekseymichailovich22976@gmail.com
ORCID iD: 0000-0002-2712-0227
SPIN-code: 1107-0875

MD, Graduate student, Assistant of the Department

Russian Federation, Samara

Yu. V. Grigoryeva

Samara State Medical University

Email: histology@bk.ru
ORCID iD: 0000-0002-7228-1003
SPIN-code: 6033-0205

PhD, Candidate of Medical Sciences, Associate Professor of the Department

Russian Federation, Samara

D. V. Duplyakov

Samara Regional Cardiology Dispensary; Samara State Medical University

Email: duplyakov@yahoo.com
ORCID iD: 0000-0002-6453-2976
SPIN-code: 5665-9578

PhD, Doctor of Medical Sciences, Professor of the Department

Russian Federation, Samara

References

  1. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis. 1970;23(7):455–468. doi: 10.1016/0021-9681(70)90054-8.
  2. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность в клинической практике. Часть 1 // Архив внутренней медицины. — 2011. — №1. — С. 16–20. [Vertkin AL, Rumyantsev MA, Skotnikov AS. Comorbidity in clinical practice. Part 1. Russ Arch Internal Med. 2011;(1):16–20. (In Russ).] doi: 10.20514/2226-6704-2011-0-1-16-20.
  3. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность в клинической практике // Архив внутренней медицины. — 2011. — №2. — С. 20–24. [Vertkin AL, Rumyantsev MA, Skotnikov AS. Comorbidity in clinical practice. Russ Arch Internal Med. 2011;(2):20–24. (In Russ).] doi: 10.20514/2226-6704-2011-0-2-20-24.
  4. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность // Клиническая медицина. — 2012. — Т.90. — №10. — С. 4–11. [Vertkin AL, Rumyantsev MA, Skotnikov AS. Comorbidity. Сlinical medicine. 2012;90(10):4–11. (In Russ).]
  5. Наумова Л.А., Осипова О.Н. Коморбидность: механизмы патогенеза, клиническое значение // Современные проблемы науки и образование. — 2016. — №5. — С. 105. [Naumova LA, Osipova ON. Comorbidity: mechanisms of pathogenesis, clinical significance. Modern problems of science and education. 2016;(5):105. (In Russ).]
  6. Тарловская Е.И. Коморбидность и полиморбидность — современная трактовка и насущные задачи, стоящие перед терапевтическим сообществом // Кардиология. — 2018. — Т.58. — №S9. — С. 29–38. [Tarlovskaya EI. Comorbidity and polymorbidity -a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018;58(S9):29–38. (In Russ).] doi: 10.18087/cardio.2562.
  7. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9(7):e102149. doi: 10.1371/journal.pone.0102149.
  8. Turner A, Mulla A, Booth A, et al. An evidence synthesis of the international knowledge base for new care models to inform and mobilise knowledge for multispecialty community providers (MCPs). Syst Rev. 2016;5(1):167. doi: 10.1186/s13643-016-0346-x.
  9. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–439. doi: 10.1016/j.arr.2011.03.003.
  10. Booth HP, Prevost AT, Gulliford MC. Impact of body mass index on prevalence of multimorbidity in primary care: cohort study. Fam Pract. 2014;31(1):38–43. doi: 10.1093/fampra/cmt061.
  11. Nagel G, Peter R, Braig S, et al. The impact of education on risk factors and the occurrence of multimorbidity in the EPIC-heidelberg cohort. BMC Public Health. 2008;8:384. doi: 10.1186/1471-2458-8-384.
  12. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/jogh.05-020415.
  13. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi: 10.1016/S2213-2600(17)30293-X.
  14. Chen W, Thomas J, Sadatsafavi M, Fitzgerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi: 10.1016/S2213-2600(15)00241-6.
  15. Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3(8):593–595. doi: 10.1016/S2213-2600(15)00279-9.
  16. Roversi S, Fabbri LM, Sin DD, et al. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med. 2016;194(11):1319–1336. doi: 10.1164/rccm.201604-0690SO.
  17. Mullerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. doi: 10.1378/chest.12-2847.
  18. Григорьева Н.Ю., Майорова М.В., Королева М.Е., Самолюк М.О. Особенности формирования и развития сердечно-сосудистых заболеваний у больных хронической обструктивной болезнью легких // Терапевтический архив. — 2019. — Т.91. — №1. — С. 16–47. [Grigoryeva NYu, Maiorova IV, Korolyova ME, Samolyuk MO. Comorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Ther Arch. 2019;91(1):16–47. (In Russ).] doi: 10.26442/00403660.2019.01.000027.
  19. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015;109(11):1371–1380. doi: 10.1016/j.rmed.2015.07.014.
  20. Morgan AD, Sharma C, Rothnie KJ, et al. Chronic obstructive pulmonary disease and the risk of stroke. Ann Am Thorac Soc. 2017;14(5):754–765. doi: 10.1513/AnnalsATS.201611-932SR.
  21. Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences-comorbidities network study. Am J Respir Crit Care Med. 2017;195(2):189–197. doi: 10.1164/rccm.201602-0354OC.
  22. Brusselle G, Bracke K, De Pauw M. Peripheral artery disease in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(2):148–150. doi: 10.1164/rccm.201608-1712ED.
  23. Franssen FM, Soriano JB, Roche N, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016;194(5):568–576. doi: 10.1164/rccm.201512-2480OC.
  24. Леонова Е.И., Шехян Г.Г., Задионченко В.С., и др. Кардиопульмональные факторы, ассоциированные с фибрилляцией предсердий у больных хронической обструктивной болезнью легких // Рациональная фармакотерапия в кардиологии. — 2016. — Т.12 — №1. — С. 26–30. [Leonova EI, Shechyan GG, Zadionchenko VS, et al. Cardiopulmonary factors associated with atrial fibrillation in patients with chronic obstructive pulmonary disease. Rational Pharmacother Cardiol. 2016;12(1):26–30. (In Russ).] doi: 10.20996/1819-6446-2016-12-1-26-30.
  25. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi: 10.1164/rccm.201201-0034OC.
  26. Беленков Ю.Н., Цветкова О.А., Привалова Е.В., и др. Коморбидность хронической обструктивной болезни легких и сердечно-сосудистых заболеваний: место терапии современными β-адреноблокаторами // Кардиология. — 2019. — Т.59. — №6. — С. 48–55. [Belenkov YN, Tsvetkova OA, Privalova EV, et al. Comorbidity of chronic obstructive pulmonary disease and cardiovascular diseases: place of therapy with modern β-adrenoblockers. Kardiologiia. 2019;59(6):48–55. (In Russ).] doi: 10.18087/cardio.2019.6.n458.
  27. Майорова М.В., Григорьева Н.Ю., Кузнецов А.Н. Особенности ведения больных с хронической обструктивной болезнью легких, имеющих различные нарушения ритма // Медицинский альманах. — 2018. — №1. — С. 101–105. [Maiorova МV, Grigor’eva NYu, Kuznetsov AN. Features of management of patients with chronic obstructive pulmonary disease having various rhythm disturbances. Medical Almanac. 2018;(1):101–105. (In Russ).] doi: 10.21145/2499-9954-2018-1-101-105.
  28. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. doi: 10.1161/hc0902.104353.
  29. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–271. doi: 10.1016/j.jacc.2013.02.092.
  30. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580. doi: 10.1136/thx.2003.019588.
  31. De Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27(5):902–907. doi: 10.1183/09031936.06.00109605.
  32. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867–874. doi: 10.1164/rccm.200604-506OC.
  33. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. doi: 10.1161/01.cir.0000056767.69054.b3.
  34. Roversi S, Roversi P, Spadafora G, et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014;44(1):93–102. doi: 10.1111/eci.12181.
  35. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072. doi: 10.1164/rccm.201110-1792OC.
  36. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61(10):849–853. doi: 10.1136/thx.2006.059808.
  37. Marchetti N, Ciccolella DE, Jacobs MR, et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011;8(2):60–65. doi: 10.3109/15412555.2011.558541.
  38. Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798–807. doi: 10.1378/chest.12-0938.
  39. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi: 10.1056/NEJMoa1403086.
  40. John ME, Cockcroft JR, McKeever TM, et al. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2015;(10):211–221. doi: 10.2147/COPD.S76061.
  41. Seidel D, Cheung A, Suh ES, et al. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012;16(8):1015–1019. doi: 10.5588/ijtld.12.0050.
  42. Van Remoortel H, Hornikx M, Langer D, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(1):30–38. doi: 10.1164/rccm.201307-1240OC.
  43. Katajisto M, Kupiainen H, Rantanen P, et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int J Chron Obstruct Pulmon Dis. 2012;7:743–755. doi: 10.2147/COPD.S35497.
  44. Авдеев С.Н. Легочная гиперинфляция у больных ХОБЛ // Атмосфера. Пульмонология и аллергология. — 2006. — №2. — С. 11–16. [Avdeev SN. Pulmonary hyperinflation in patients with COPD. Atmosphere. Pulmonology and Allergology. 2006;(2):11–16. (In Russ).]
  45. Barnes PJ. Senescence in COPD and its comorbidities. Annu Rev Physiol. 2017;79:517–539. doi: 10.1146/annurev-physiol-022516-034314.
  46. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(7):566–571. doi: 10.1164/rccm.200809-1398OC.
  47. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006;174(8):886–893. doi: 10.1164/rccm.200509-1374OC.
  48. Tuder RM, Yoshida T, Fijalkowka I, et al. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc Am Thorac Soc. 2006;3(8):673–679. doi: 10.1513/pats.200605-124SF.
  49. Benetos A, Okuda K, Lajemi M, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001;37(2Pt2):381–385. doi: 10.1161/01.hyp.37.2.381.
  50. Minamino T, Miyauchi H, Yoshida T, et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541–1544. doi: 10.1161/01.cir.0000013836.85741.17.
  51. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012;67(7):606–612. doi: 10.1136/thoraxjnl-2011-200949.
  52. Sciurba FC, Rogers RM, Keenan RJ, et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med. 1996;334(17):1095–1099. doi: 10.1056/NEJM199604253341704.
  53. Falk JA, Martin UJ, Scharf S, Criner GJ. Lung elastic recoil does not correlate with pulmonary hemodynamics in severe emphysema. Chest. 2007;132(5):1476–1484. doi: 10.1378/chest.07-0041.
  54. Austin V, Crack PJ, Bozinovski S, et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016;130(13):1039–1050. doi: 10.1042/CS20160043.
  55. Kida Y, Goligorsky MS. Sirtuins, cell senescence, and vascular aging. Can J Cardiol. 2016;32(5):634–641. doi: 10.1016/j.cjca.2015.11.022.
  56. Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109–124. doi: 10.1007/bf00175982.
  57. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324(22):1539–1547. doi: 10.1056/NEJM199105303242203.
  58. Cohen AJ, Brauer M, Burnett R, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389(10082):1907–1918. doi: 10.1016/S0140-6736(17)30505-6.
  59. Dockery DW, Evans JS. Tallying the bills of mortality from air pollution. Lancet. 2017;389(10082):1862–1864. doi: 10.1016/S0140-6736(17)30884-X.
  60. Chaudary N, Geraci SA. Prognostic value of cardiac-specific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J Miss State Med Assoc. 2014;55(2):40–44.
  61. Harvey MG, Hancox RJ. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas. 2004;16(3):212–215. doi: 10.1111/j.1742-6723.2004.00589.x.
  62. Чаулин А.М., Карслян Л.С., Григорьева Е.В., и др. Клинико-диагностическая ценность кардиомаркеров в биологических жидкостях человека // Кардиология. — 2019. — Т.59. — №11. — С. 66–75. [Chaulin AM, Karslyan LS, Grigoryeva EV, et al. Clinical and diagnostic value of cardiac markers in human biological fluids. Kardiologiia. 2019;59(11):66–75. (In Russ).] doi: 10.18087/cardio.2019.11.n414.
  63. Чаулин А.М., Карслян Л.С., Григорьева Е.В., и др. Особенности метаболизма сердечных тропонинов (обзор литературы) // Комплексные проблемы сердечно-сосудистых заболеваний. — 2019. — Т.8. — №4. — С. 103–115. [Chaulin AM, Karslyan LS, Grigorieva EV, et al. Metabolism of cardiac troponins (literature review). Complex Issues Cardiovasc Diseas. 2019;8(4):103–115. (In Russ).] doi: 10.17802/2306-1278-2019-8-4-103-115.
  64. Чаулин А.М., Карслян Л.С., Дупляков Д.В. Некоронарогенные причины повышения тропонинов в клинической практике // Клиническая практика. — 2019. — Т.10. — №4. — C. 81–93. [Chaulin AM, Karslyan LS, Duplyakov DV. Non-coronarogenic causes of increased cardiac troponins in clinical practice. Journal of Clinical Practice. 2019;10(4):81–93. (In Russ).] doi: 10.17816/clinpract16309.
  65. Waschki B, Alter P, Zeller T, et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur Respir J. 2019. pii: 1901314. doi: 10.1183/13993003.01314-2019.
  66. Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149–164. doi: 10.1016/S2213-2600(15)00518-4.
  67. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1(1):73–83. doi: 10.1016/S2213-2600(12)70060-7.
  68. Halpin DM, Dahl R, Hallmann C, et al. Tiotropium HandiHaler and Respimat in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239–259. doi: 10.2147/COPD.S75146.
  69. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern. Med. 2013;173(13):1175–1185. doi: 10.1001/jamainternmed.2013.1016.
  70. Heindl S, Lehnert M, Criee CP, et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164(4):597–601. doi: 10.1164/ajrccm.164.4.2007085.
  71. Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014;146(6):1531–1542. doi: 10.1378/chest.14-0117.
  72. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56. doi: 10.1136/thoraxjnl-2012-201926.
  73. Rothnie KJ, Smeeth L, Herrett E, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015;101(14):1103–1110. doi: 10.1136/heartjnl-2014-307251.
  74. Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650. doi: 10.1136/bmj.f6650.
  75. Lipworth B, Wedzicha J, Devereux G, et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016;48(3):880–888. doi: 10.1183/13993003.01847-2015.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. General risk factors and pathophysiological mechanisms for chronic obstructive pulmonary disease and cardiovascular disease

Download (420KB)
Indexing metadata

Copyright (c) 2020 Chaulin A.M., Grigoryeva Y.V., Duplyakov D.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies